glp·helper
glphelper.com/semaglutide/arizona/tempe
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Tempe, AZ

Verified Semaglutide providers in Tempe, AZ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
25
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Arizona
25 of 25 shown

Find a Semaglutide provider in Arizona.

Every entry is checked against the NPI registry and the Arizona medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Arizona city · /semaglutide/arizona/{city}
§ 03Getting Semaglutide in Arizona
25 providers · 8 metros

How a prescription works in Arizona.

You don’t have to leave Arizona to start. Because semaglutide isn't a controlled substance, a Arizona-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 25 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in Arizona
Semaglutide (semaglutide) is a GLP-1, not a controlled substance, so a Arizona-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
AZ-licensed clinicians
Any physician, nurse practitioner, or PA licensed in Arizona can prescribe Semaglutide. The 25 providers below are checked against the NPI registry and the Arizona board.
Medicaid (weight loss)
Diabetes only
As of April 2026, Arizona Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Arizona’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Tempe

Tempe, Arizona has a population of 180,587 people. The adult obesity rate in Tempe is an age-adjusted estimate of 29.7%, 3.6 percentage points below the Arizona state rate of 33.3%. Diagnosed diabetes reaches 9.1% of adults in Tempe. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 18.1% of adults in Tempe.

of Tempe adults have obesity
29.7%
diagnosed diabetes
9.1%
no regular physical activity
18.1%

Age-adjusted estimates for Tempe, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossdo oral GLP-1 pills work
§ 05Support around Semaglutide in Tempe
6 nutritionists

The prescription is one part. Here is the rest, in Tempe.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Tempe, AZ, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Selange Giannetto
NUTRITIONIST
Nutritionist
5626 S Marine Dr
Call 630-715-5838NPI 1013665744
Christine Hayes, B.S., R.N
NUTRITIONIST
Nutritionist · Education
1920 E Baseline Rd
Call 480-345-5000NPI 1982895389
John Kinsey
NUTRITIONIST
Nutritionist
1010 W Riviera Cir
Call 520-229-7329NPI 1235933524
Jennifer Ortlepp, MS,
NUTRITIONIST
Nutritionist
4404 E Pueblo Ave
Call 928-813-5448NPI 1700543469
Kelly Teal
NUTRITIONIST
Nutritionist
2066 E Ellis Dr
Call 520-709-1211NPI 1407744683
Christopher Yedlicka
NUTRITIONIST
Nutritionist
8400 S Kyrene Rd Ste 103
Call 602-698-7111NPI 1669056727

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

EōS Fitness
GYM
4.4 on Google · 2165 reviews
1840 E Warner Rd Ste 111
Website
LA Fitness
GYM
4.3 on Google · 1185 reviews
63 E Southern Ave
Website
Planet Fitness
GYM
4.4 on Google · 996 reviews
1405 W Southern Ave
Website
After It Training - Tempe
GYM
4.8 on Google · 404 reviews
250 W Baseline Rd #101
Website
Muscle Factory Gym
GYM
4.6 on Google · 269 reviews
1301 E University Dr Unit 125
Website
VŌLITION | Group Fitness & Personal Training Gym in Tempe
GYM
5.0 on Google · 218 reviews
2155 E University Dr #101
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Arizona

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Arizona

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]